The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Thakur, Geeta A ^a,b   Grizenko, Natalie ^a,b   Sengupta, Sarojini M ^b   Schmitz, Norbert ^a,b   Joober, Ridha ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PLACEBO; SEROTONIN TRANSPORTER; CENTRAL STIMULANT AGENT; SLC6A4 PROTEIN, HUMAN;

AGAR GEL ELECTROPHORESIS; ALLELE; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD BEHAVIOR; CLINICAL TRIAL; COMORBIDITY; CONDUCT DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HOME ENVIRONMENT; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; OPPOSITIONAL DEFIANT DISORDER; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; GENETICS; PARENT; PROMOTER REGION; TEACHING;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PARENTS; PLACEBOS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TEACHING; TREATMENT OUTCOME;

EID: 77954873626     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-50     Document Type: Article

References (50)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005, 366(9481):237-248. 10.1016/S0140-6736(05)66915-2, 16023516.
2. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57(11):1313-1323. 10.1016/j.biopsych.2004.11.024, 15950004.
3. Ioannidis JP. Why most published research findings are false. PLoS Med 2005, 2(8):e124. 10.1371/journal.pmed.0020124, 1182327,1182327, 16060722.
4. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998, 155(10):1325-1331.
5. Joober R, Grizenko N, Sengupta S, Amor LB, Schmitz N, Schwartz G, Karama S, Lageix P, Fathalli F, Torkaman-Zehi A, et al. Dopamine transporter 3'-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology 2007, 32(6):1370-1376. 10.1038/sj.npp.1301240, 17063150.
6. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C, Kim SJ, Cook EH. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 2005, 30(7):1374-1382.
7. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379(6566):606-612. 10.1038/379606a0, 8628395.
8. Gainetdinov RR, Caron MG. Genetics of childhood disorders: XXIV. ADHD, part 8: hyperdopaminergic mice as an animal model of ADHD. J Am Acad Child Adolesc Psychiatry 2001, 40(3):380-382. 10.1097/00004583-200103000-00020, 11288782.
9. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999, 283(5400):397-401. 10.1126/science.283.5400.397, 9888856.
10. Marx J. How stimulant drugs may calm hyperactivity. Science 1999, 283(5400):306. 10.1126/science.283.5400.306, 9925481.
11. Volkow ND, Gatley SJ, Fowler JS, Wang GJ, Swanson J. Serotonin and the therapeutic effects of ritalin. Science 2000, 288(5463):11. 10.1126/science.288.5463.11a, 10766624.
12. Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv 2004, 4(2):109-123. 10.1124/mi.4.2.8, 15087484.
13. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996, 66(6):2621-2624.
14. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274(5292):1527-1531. 10.1126/science.274.5292.1527, 8929413.
15. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006, 78(5):815-826. 10.1086/503850, 1474042, 16642437.
16. Cadoret RJ, Langbehn D, Caspers K, Troughton EP, Yucuis R, Sandhu HK, Philibert R. Associations of the serotonin transporter promoter polymorphism with aggressivity, attention deficit, and conduct disorder in an adoptee population. Compr Psychiatry 2003, 44(2):88-101. 10.1053/comp.2003.50018, 12658617.
17. Curran S, Purcell S, Craig I, Asherson P, Sham P. The serotonin transporter gene as a QTL for ADHD. Am J Med Genet B Neuropsychiatr Genet 2005, 134B(1):42-47. 10.1002/ajmg.b.30118, 15719397.
18. Kent L, Doerry U, Hardy E, Parmar R, Gingell K, Hawi Z, Kirley A, Lowe N, Fitzgerald M, Gill M, et al. Evidence that variation at the serotonin transporter gene influences susceptibility to attention deficit hyperactivity disorder (ADHD): analysis and pooled analysis. Mol Psychiatry 2002, 7(8):908-912. 10.1038/sj.mp.4001100, 12232786.
19. Kim SJ, Badner J, Cheon KA, Kim BN, Yoo HJ, Kim SJ, Cook E, Leventhal BL, Kim YS. Family-based association study of the serotonin transporter gene polymorphisms in Korean ADHD trios. Am J Med Genet B Neuropsychiatr Genet 2005, 139B(1):14-18. 10.1002/ajmg.b.30214, 16082698.
20. Langley K, Payton A, Hamshere ML, Pay HM, Lawson DC, Turic D, Ollier W, Worthington J, Owen MJ, O'Donovan MC, et al. No evidence of association of two 5HT transporter gene polymorphisms and attention deficit hyperactivity disorder. Psychiatr Genet 2003, 13(2):107-110. 10.1097/00041444-200306000-00009, 12782968.
21. Manor I, Eisenberg J, Tyano S, Sever Y, Cohen H, Ebstein RP, Kotler M. Family-based association study of the serotonin transporter promoter region polymorphism (5-HTTLPR) in attention deficit hyperactivity disorder. Am J Med Genet 2001, 105(1):91-95. 10.1002/1096-8628(20010108)105:1<91::AID-AJMG1069>3.0.CO;2-V, 11425009.
22. Xu X, Mill J, Chen CK, Brookes K, Taylor E, Asherson P. Family-based association study of serotonin transporter gene polymorphisms in attention deficit hyperactivity disorder: no evidence for association in UK and Taiwanese samples. Am J Med Genet B Neuropsychiatr Genet 2005, 139B(1):11-13. 10.1002/ajmg.b.30203, 16082690.
23. Beitchman JH, Davidge KM, Kennedy JL, Atkinson L, Lee V, Shapiro S, Douglas L. The serotonin transporter gene in aggressive children with and without ADHD and nonaggressive matched controls. Ann N Y Acad Sci 2003, 1008:248-251. 10.1196/annals.1301.025, 14998889.
24. Retz W, Thome J, Blocher D, Baader M, Rosler M. Association of attention deficit hyperactivity disorder-related psychopathology and personality traits with the serotonin transporter promoter region polymorphism. Neurosci Lett 2002, 319(3):133-136. 10.1016/S0304-3940(01)02575-7, 11834311.
25. Seeger G, Schloss P, Schmidt MH. Functional polymorphism within the promotor of the serotonin transporter gene is associated with severe hyperkinetic disorders. Mol Psychiatry 2001, 6(2):235-238. 10.1038/sj.mp.4000820, 11317229.
26. Zhao AL, Su LY, Zhang YH, Tang BS, Luo XR, Huang CX, Su QR. Association analysis of serotonin transporter promoter gene polymorphism with ADHD and related symptomatology. Int J Neurosci 2005, 115(8):1183-1191. 10.1080/00207450590914545, 16040360.
27. Zoroglu SS, Erdal ME, Alasehirli B, Erdal N, Sivasli E, Tutkun H, Savas HA, Herken H. Significance of serotonin transporter gene 5-HTTLPR and variable number of tandem repeat polymorphism in attention deficit hyperactivity disorder. Neuropsychobiology 2002, 45(4):176-181. 10.1159/000063667, 12097805.
28. Lahey BB, Applegate B, McBurnett K, Biederman J, Greenhill L, Hynd GW, Barkley RA, Newcorn J, Jensen P, Richters J, et al. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry 1994, 151(11):1673-1685.
29. National Institute of Mental Health NIMH DISC-IV 1998, Joy and William Ruane Center to Identify and Treat Mood Disorders, New York: Columbia University, National Institute of Mental Health.
30. Achenbach TM. The child behavior checklist/4-18 and 1991 profile 1991, Burlington, Vermont: University of Vermont.
31. Conners CK. Rating scales for use in assessment and clinical trials with children. Ritalin Theory and Practice 1999, 113-126. New York: Mary Ann Liebert, Inc, Greenhill LL, Osman BB.
32. Conners CK. Conners' Rating Scales-Revised Technical Manual 1997, New York: Multi Health Systems.
33. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Cmaj 2001, 165(11):1475-1488. 81663, 11762571.
34. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001, 108(4):1033-1044. 10.1542/peds.108.4.1033, 11581465.
35. Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science 1977, 198(4323):1274-1276. 10.1126/science.337493, 337493.
36. Tannock R, Schachar R, Logan G. Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children. J Abnorm Child Psychol 1995, 23(2):235-266. 10.1007/BF01447091, 7642836.
37. Evans SW, Pelham WE, Smith BH, Bukstein O, Gnagy EM, Greiner AR, Altenderfer L, Baron-Myak C. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol 2001, 9(2):163-175. 10.1037/1064-1297.9.2.163, 11518092.
38. Steiger H, Joober R, Israel M, Young SN, Ng Ying Kin NM, Gauvin L, Bruce KR, Joncas J, Torkaman-Zehi A. The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes. Int J Eat Disord 2005, 37(1):57-60. 10.1002/eat.20073, 15690467.
39. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models 2006, Cary, North Carolina: SAS Institute Inc, 2.
40. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004, 61(3):310-317. 10.1001/archpsyc.61.3.310, 14993119.
41. Senn S. Cross-over Trials in Clinical Research 2002, New York: John Wiley, 2.
42. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990, 86(2):184-192.
43. Lott DC, Kim SJ, Cook EH, de Wit H. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 2005, 30(3):602-609. 10.1038/sj.npp.1300637, 15602501.
44. Tharoor H, Lobos EA, Todd RD, Reiersen AM. Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. Am J Med Genet B Neuropsychiatr Genet 2008, 147B(4):527-530. 10.1002/ajmg.b.30637, 17948872.
45. Zeni CP, Guimaraes AP, Polanczyk GV, Genro JP, Roman T, Hutz MH, Rohde LA. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2007, 144B(3):391-394. 10.1002/ajmg.b.30474, 17171656.
46. Stein MT. When parents and teachers disagree about a child's behavior: an opportunity for further evaluations. J Dev Behav Pediatr 2004, 25(1):50-51. discussion 52, 10.1097/00004703-200402000-00009, 14767357.
47. Martin N, Scourfield J, McGuffin P. Observer effects and heritability of childhood attention-deficit hyperactivity disorder symptoms. Br J Psychiatry 2002, 180:260-265. 10.1192/bjp.180.3.260, 11872519.
48. Sherman DK, McGue MK, Iacono WG. Twin concordance for attention deficit hyperactivity disorder: a comparison of teachers' and mothers' reports. Am J Psychiatry 1997, 154(4):532-535.
49. Thapar A, Langley K, O'Donovan M, Owen M. Refining the attention deficit hyperactivity disorder phenotype for molecular genetic studies. Mol Psychiatry 2006, 11(8):714-720. 10.1038/sj.mp.4001831, 16702977.
50. Faraone SV, Biederman J, Zimmerman B. Correspondence of parent and teacher reports in medication trials. Eur Child Adolesc Psychiatry 2005, 14(1):20-27. 10.1007/s00787-005-0415-5, 15756512.